Volume 142, Issue 2, Pages e12 (February 2012)

Slides:



Advertisements
Similar presentations
Volume 133, Issue 2, Pages (August 2007)
Advertisements

Volume 124, Issue 5, Pages (May 2003)
Volume 151, Issue 4, Pages (October 2016)
Volume 138, Issue 2, Pages e3 (February 2010)
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 136, Issue 2, Pages e5 (February 2009)
Volume 133, Issue 6, Pages (December 2007)
Volume 144, Issue 5, Pages e10 (May 2013)
Volume 138, Issue 3, Pages e2 (March 2010)
Volume 144, Issue 5, Pages e3 (May 2013)
Volume 143, Issue 5, Pages (November 2012)
Volume 154, Issue 4, Pages e6 (March 2018)
Volume 136, Issue 4, Pages e3 (April 2009)
Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy  Raphaela.
Volume 131, Issue 2, Pages (August 2006)
Volume 134, Issue 4, Pages (April 2008)
Volume 133, Issue 4, Pages (October 2007)
Volume 136, Issue 3, Pages (March 2009)
Volume 28, Issue 2, Pages (February 2008)
Volume 136, Issue 2, Pages (February 2009)
Volume 141, Issue 4, Pages e5 (October 2011)
Volume 138, Issue 7, Pages (June 2010)
Volume 136, Issue 7, Pages e4 (June 2009)
Volume 130, Issue 2, Pages (February 2006)
Volume 143, Issue 5, Pages e4 (November 2012)
Outcomes Among Living Liver Donors
Volume 137, Issue 6, Pages e2 (December 2009)
Volume 133, Issue 2, Pages (August 2007)
This Month in Gastroenterology
Volume 136, Issue 1, Pages (January 2009)
Volume 124, Issue 5, Pages (May 2003)
Volume 133, Issue 3, Pages (September 2007)
Volume 132, Issue 4, Pages (April 2007)
Volume 142, Issue 2, Pages e2 (February 2012)
Volume 134, Issue 1, Pages e1 (January 2008)
Volume 141, Issue 3, Pages (September 2011)
Volume 143, Issue 6, Pages e4 (December 2012)
Volume 141, Issue 4, Pages e1 (October 2011)
Volume 151, Issue 4, Pages (October 2016)
Volume 135, Issue 3, Pages e5 (September 2008)
Volume 153, Issue 5, Pages e2 (November 2017)
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Volume 127, Issue 3, Pages (September 2004)
Volume 136, Issue 2, Pages (February 2009)
Requirements for allergen-induced airway inflammation and hyperreactivity in CD4- deficient and CD4-sufficient HLA-DQ transgenic mice  Svetlana P. Chapoval,
Volume 134, Issue 4, Pages e2 (April 2008)
Volume 147, Issue 1, Pages (July 2014)
Volume 138, Issue 2, Pages e3 (February 2010)
Volume 139, Issue 3, Pages e3 (September 2010)
Volume 140, Issue 2, Pages e4 (February 2011)
Volume 115, Issue 4, Pages (October 1998)
Volume 138, Issue 2, Pages e4 (February 2010)
Volume 132, Issue 1, Pages (January 2007)
Volume 20, Issue 6, Pages (August 2017)
Volume 143, Issue 1, Pages e3 (July 2012)
Therapeutic Action of Ghrelin in a Mouse Model of Colitis
Volume 135, Issue 5, Pages e5 (November 2008)
Antigen-Presenting Cell Production of IL-10 Inhibits T-Helper 1 and 17 Cell Responses and Suppresses Colitis in Mice  Bo Liu, Susan L. Tonkonogy, R. Balfour.
Volume 135, Issue 2, Pages e2 (August 2008)
Volume 20, Issue 2, Pages (February 2013)
Leptin: A pivotal mediator of intestinal inflammation in mice
Ulrich Zügel, Khusru Asadullah  Journal of Investigative Dermatology 
Volume 141, Issue 3, Pages (September 2011)
Volume 153, Issue 3, Pages e4 (September 2017)
Volume 135, Issue 3, Pages (September 2008)
Volume 132, Issue 2, Pages (February 2007)
Volume 131, Issue 6, Pages (December 2006)
Volume 133, Issue 3, Pages (September 2007)
Volume 137, Issue 6, Pages e2 (December 2009)
Volume 138, Issue 2, Pages e4 (February 2010)
Presentation transcript:

Volume 142, Issue 2, Pages 316-325.e12 (February 2012) The Copolymer P(HEMA-co-SS) Binds Gluten and Reduces Immune Response in Gluten-Sensitized Mice and Human Tissues  Maud Pinier, Gregor Fuhrmann, Heather J. Galipeau, Nathalie Rivard, Joseph A. Murray, Chella S. David, Hana Drasarova, Ludmila Tuckova, Jean–Christophe Leroux, Elena F. Verdu  Gastroenterology  Volume 142, Issue 2, Pages 316-325.e12 (February 2012) DOI: 10.1053/j.gastro.2011.10.038 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 P(HEMA-co-SS) decreases the formation of peptides (A) QLQPFPQPQLPY and (B) PQPQLPYPQPQLPYPQPQPF from wheat gluten. Digested gluten samples were analyzed by LC-MS. Relative abundance was determined by comparison with the gluten digest in the absence of P(HEMA-co-SS). Mean ± SEM displayed from 3 injections of 3 independent samples, *P ≤ .001 Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 P(HEMA-co-SS) is poorly absorbed and mainly excreted in the feces. Excretion profiles and biodistribution of [3H]-P(HEMA-co-SS) in nonsensitized (white bars) and gluten-sensitized (black bars) HCD4/DQ8 mice after single oral dosing (240 mg/kg, 22.4 μCi/kg). (A) Cumulative dose excreted in feces, (B) cumulative dose excreted in urine, and (C) blood, liver, and kidney levels at the time the mice were killed. Mean ± SEM, n = 4/group. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 Administration of P(HEMA-co-SS) to gluten-sensitized HCD4/DQ8 mice challenged with wheat gluten mixture decreased (A) 51Cr-EDTA flux (paracellular permeability) and (B) intestinal tissue conductance compared with untreated nonsensitized mice. Controls: nonsensitized mice gavaged with BSA and starch (n = 12–13); gluten mixture group: gluten-sensitized mice gavaged with gluten/BSA/starch (n = 9–10); P(HEMA-co-SS) (HD) + gluten mixture group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (gluten/polymer 1:2 wt/wt) (n = 9–10); P(HEMA-co-SS) (LD) + gluten mixture group (second treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (gluten/polymer 2:1 wt/wt) (n = 4). Mean ± SEM, *P ≤ .02 for Cr-EDTA and P ≤ .01 for conductance. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 Administration of P(HEMA-co-SS) to gluten-sensitized mice challenged with gluten-food mixture tended to reduce splenocyte proliferation after incubation with PT-gliadin. Data represent the stimulation index from mean [3H]thymidine incorporation for triplicate cultures. Mean ± SEM (n = 8–9/group), *P ≤ .001. Controls: nonsensitized mice gavaged with BSA and starch; gluten mixture group: gluten-sensitized mice gavaged with gluten/BSA/starch; P(HEMA-co-SS) + gluten mixture group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (HD). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 5 Modulation of cytokine production in splenocyte culture supernatants after PT-gliadin incubation: (A) IL-10, (B) TNF-α, and (C) MCP-1. IL-10 secretion was increased in gluten-sensitized mice receiving P(HEMA-co-SS) compared with controls. Administration of P(HEMA-co-SS) to gluten-sensitized mice led to lower TNF-α and MCP-1 levels in culture supernatants after PT stimulation. Controls: nonsensitized mice gavaged with BSA and starch; gluten mixture: gluten-sensitized mice gavaged with gluten/BSA/starch; P(HEMA-co-SS) + gluten mixture (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (HD). Mean ± SEM (n = 10/group), *P ≤ .001. In culture supernatants from the splenocytes incubated with medium alone, cytokines were below the limit of detection (LOD; dashed lines) (LODIL-10= 17.5 pg/mL; LODTNF-α = 7.3 pg/mL; LODMCP-1 = 52.7 pg/mL). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 6 Administration of P(HEMA-co-SS) reduced the morphologic intestinal abnormalities induced by long-term administration of gluten. (A) Controls: nonsensitized mice gavaged with BSA and starch, (B) gluten mixture group: gluten-sensitized mice gavaged with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg), (C) P(HEMA-co-SS) + gluten mixture group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) (4 mg) and subsequently with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg). Challenges were performed twice a day, 3 times a week, for 3 weeks. Representative H&E-stained jejunum section of the various groups observed by optical microscopy. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Figure 7 Incubation with P(HEMA-co-SS) abolished gliadin-induced TNF-α secretion (white bars) in culture supernatants of biopsy specimens from patients with celiac disease. P(HEMA-co-SS) alone or in P-digest did not affect gliadin-induced IL-10 secretion (black bars). The negative control corresponds to biopsy specimens incubated with medium only. Mean ± SEM (n = 4), *P ≤ .05 vs all other TNF-α groups. BLQ: below limit of quantification (<31.3 pg/mL for IL-10 and <15.6 pg/mL for TNF-α). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 1 (A) 51Cr-EDTA flux (paracellular permeability), (B) intestinal tissue conductance and (C) anti-gliadin IgA in intestinal washes in non-sensitized (n = 12–14) vs. gliadin sensitized (n = 8–9) HCD4/DQ8 mice. Mean ± SEM. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 2 P(HEMA-co-SS) decreases the formation of the 13-mer peptide, LGQQQPFPPQQPY from wheat gliadin. Digested gliadin samples were analyzed by LC-MS. Relative abundance was determined by comparison with the gliadin digest in the absence of P(HEMA-co-SS) (positive control). Mean ± SEM displayed from 3 injections of 3 independent samples, *P ≤ 0.001. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 3 P(HEMA-co- SS) decreases the formation of peptides YPTSPQQSGQGQQL (A), LQPQQPFPQQPQQPFPQ (B) and SQQQQPPF (C) from wheat gluten. Digested gluten samples were analyzed by LC-MS. Relative abundance was determined by comparison with the gluten digest in the absence of P(HEMA-co-SS). Mean ± SEM displayed from 3 injections of 3 independent samples, *P ≤ 0.001. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 4 P(HEMA-co-SS) decreases the formation of peptides PQQPFPPQQPFPQQPPFW (A), PQQPQQPFPQPQQPFRQ (B), PQQPFPQQPQQPFPQPQQPF (C), and LERPQQLFPQWQPLPQQPPFL (D) from barley hordein. Digested hordein samples were analyzed by LC-MS. Relative abundance was determined by comparison with the hordein digest in the absence of P(HEMA-co-SS) (positive control). Mean ± SEM displayed from 3 injections of 3 independent samples, *P ≤ 0.005. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 5 P(HEMA-co-SS) is and mainly excreted in feces and poorly absorbed. Pharmacokinetics, excretion profiles and biodistribution of [3H]-P(HEMA-co-SS) in Sprague Dawley rats after single oral dosing (150 mg/kg, 6.4 μCi/kg). (A) Blood concentrations, (B) cumulative dose excreted in the feces, (C) cumulative dose excreted in urine, (D) organ distribution. Mean ± SEM (n = 7). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 6 P(HEMA-co-SS) is and mainly excreted in feces and poorly absorbed. Pharmacokinetics, excretion profiles and biodistribution of [3H]-P(HEMA-co-SS) in Sprague Dawley rats, after a polymer exposure for 21 days (100 mg/kg/day) and a single dose of [3H]-P(HEMA-co-SS) (150 mg/kg, 6.4 μCi/kg) at day 22. (A) Blood concentrations, (B) cumulative dose excreted in the feces, (C) cumulative dose excreted in urine, (D) organ distribution. Mean ± SEM (n = 7). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 7 (A) 51Cr-EDTA flux (paracellular permeability), (B) intestinal tissue conductance, (C) anti-gliadin IgA in intestinal washes. Controls: non-sensitized mice gavaged with BSA and starch (n = 12–14); gluten mixture (HL) (gluten mixture with a higher level of gluten, 4 mg) group: gluten-sensitized mice gavaged with wheat gluten (4 mg)/BSA (2 mg)/starch (2 mg) (n = 8–9); P(HEMA- co-SS) + gluten mixture (HL) group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) (4 mg) and subsequently with wheat gluten (4 mg)/BSA (2 mg)/starch (2 mg) (gluten/polymer 1:1 w/w) (n = 8–9). Mean ± SEM *P ≤ 0.02. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 8 Administration of P(HEMA-co-SS) to gluten-sensitized HCD4/DQ8 mice challenged with gluten-food mixture decreased IgA levels. Gluten sensitization and gluten-food mixture challenge to HCD4/DQ8 mice increased OD levels for anti-gliadin IgA in intestinal washes. In gluten- sensitized mice, administration of P(HEMA-co-SS) returned IgA levels to control values. The control group was used as reference (100% optical density at 450 nm, OD450). Mean ± SEM, *P ≤ 0.001. Controls: non-sensitized mice gavaged with BSA and starch (n = 14); gluten mixture group: gluten- sensitized mice gavaged with gluten/BSA/starch (n = 10); P(HEMA-co-SS) (HD) + gluten mixture group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (gluten/polymer 1:2 w/w) (n = 10); P(HEMA-co-SS) (LD) + gluten mixture group (second treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) and subsequently with gluten/BSA/starch (gluten/polymer 2:1 w/w) (n = 6). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 9 Effect of treatment following a chronic exposure to gluten: (A) 51Cr- EDTA flux (paracellular permeability), (B) intestinal tissue conductance, (C) anti-gliadin IgA in intestinal washes. Controls: non-sensitized mice gavaged with BSA and starch; gluten mixture group: gluten-sensitized mice gavaged with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg); P(HEMA-co-SS) + gluten mixture group (treatment group): gluten-sensitized mice gavaged first with P(HEMA-co-SS) (4 mg) and subsequently with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg). Challenges were performed twice a day, 3 times a week for 3 weeks. Mean ± SEM, (n = 9–10), *P ≤ 0.02; #P = 0.0585). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 10 P(HEMA-co-SS) did not affect the evolution of the weight gain in vivo of HLA-DQ8 transgenic mice after a 3 week challenge. Controls: non-sensitized mice gavaged with BSA and starch; gluten mixture group: gluten-sensitized mice gavaged with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg); Treatment group: gluten-sensitized mice gavaged first with P(HEMA-co-SS) (4 mg) and subsequently with wheat gluten (2 mg)/BSA (2 mg)/starch (2 mg). Challenges were performed twice a day, 3 times a week for 3 weeks (n = 10). Mean ± SD. Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 11 Production of TNF-α (white bars) and IL-10 (black bars) in culture supernatants from biopsies of CD patients after incubation with P(HEMA-co-SS) alone or with P- gliadin +/− P(HEMA-co-SS). Negative control corresponds to biopsies incubated with medium only. Mean ± SEM (n = 5), *P ≤ 0.05. BLQ: below limit of quantification (<31.3 pg/mL for IL-10 and <15.6 pg/mL for TNF-α). Gastroenterology 2012 142, 316-325.e12DOI: (10.1053/j.gastro.2011.10.038) Copyright © 2012 AGA Institute Terms and Conditions